Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Efficacy of Alogliptin as Monotherapy or Add on Therapy in Indian Patients With Type 2 Diabetes Mellitus
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 18 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Jun 2017 Planned initiation date changed from 15 Jun 2017 to 30 Jul 2017.